The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GIST) with different KIT genotypes: Post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials.
 
Michael C. Heinrich
Honoraria - Novartis
Consulting or Advisory Role - Blueprint Medicines; Deciphera; Novartis; Theseus Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Patent on treatment of GIST-licensed to Novartis (Inst)
 
Jian Li
No Relationships to Disclose
 
Xinhua Zhang
No Relationships to Disclose
 
Robin L Jones
Consulting or Advisory Role - Adaptimmune; Astex Pharmaceuticals; Athenex; Bayer; Blueprint Genetics; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immune Design; Immunicum; Karma Oncology; Lilly; Merck; Mundipharma; PharmaMar; SpringWorks Therapeutics; SynOX; TRACON Pharma
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories
Honoraria - CStone Pharmaceuticals
Consulting or Advisory Role - Bayer; BioAtla; Blueprint Medicines; Daiichi; deciphera; Immunicum; Kayothera; Lilly; MORE Health; Research to Practice; UpToDate
Research Funding - BioAtla; Blueprint Medicines (Inst); Daiichi Sankyo RD Novare (Inst); Deciphera (Inst); Eisai (Inst); IDRx (Inst); Merck (Inst); SpringWorks Therapeutics (Inst); Theseus Pharmaceuticals (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UptoDate
Expert Testimony - Bayer
Other Relationship - Research to Practice; WCG
 
Jonathan C. Trent
Consulting or Advisory Role - AADi; Agios; Bayer; Blueprint Medicines; Boehringer Ingelheim; C4 Therapeutics; Cogent Medicine; Daiichi Sankyo; Deciphera; Epizyme; Foghorn Therapeutics; SERVIER
 
Cesar Serrano
Honoraria - Deciphera; PharmaMar
Consulting or Advisory Role - Blueprint Medicines; Cogent Biosciences; Deciphera; IDRX; Immunicum
Research Funding - IDRX (Inst); Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Bayer; Gilead Sciences; Pfizer; PharmaMar
 
Yanhong Deng
No Relationships to Disclose
 
Sebastian Bauer
Honoraria - Deciphera; GlaxoSmithKline; Novartis; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; Adcendo; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Exelixis; GlaxoSmithKline; Janssen-Cilag; Lilly; Mundipharma; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar
 
Shirong Cai
No Relationships to Disclose
 
Xin Wu
No Relationships to Disclose
 
Yongjian Zhou
No Relationships to Disclose
 
Kaixiong Tao
No Relationships to Disclose
 
Zhichao Zheng
No Relationships to Disclose
 
Jun Zhang
No Relationships to Disclose
 
Yuehong Cui
No Relationships to Disclose
 
Hui Cao
No Relationships to Disclose
 
Meining Wang
Employment - CStone Pharmaceuticals
Honoraria - CStone Pharmaceuticals
 
Jin Hu
Employment - CStone Pharmaceuticals
Stock and Other Ownership Interests - CStone Pharmaceuticals
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squib; Daiichi Sankyo; Harbour BioMed; Merck; Mingji biopharmaceutical; MSD; Roche; Sanofi
Research Funding - Baiji Shenzhou (Beijing) Biotechnology (Inst); Beijing Xiantong Biomedical Technology (Inst); CANbridge Pharmaceuticals (Inst); Jacobio (Inst); Nanjing Yaojieankang Biotechnology (Inst); QiLu Pharmaceutical (Inst); Zaiding Pharmaceutical (Inst)